Cell Therapeutics Seeks Pixantrone Approval
Ryan McBride4/14/09
Cell Therapeutics says that it has begun a rolling submission of an application to the FDA to garner approval of its drug pixantrone, a treatment for relapsed or refractory aggressive cases of non-Hodgkin’s lymphoma. The Seattle-based drug developer (NASDAQ:CTIC)—which revealed yesterday that it secured $15 million from institutional investor Cranshire Capital—plans to complete submission of its FDA application for pixantrone by the end of June and hopes to gain approval for the drug in the fourth quarter of 2009.
